Structure Therapeutics Inc. 8-K

What Happened

• On December 30, 2025, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Inc., entered into a licensing agreement (the “GNE Agreement”) with Genentech, Inc. and F. Hoffmann‑La Roche Ltd. Gasherbrum granted GNE a non-exclusive, sublicensable, royalty-bearing license under certain Gasherbrum patents to make, use, sell, offer for sale and import products containing CT‑996. Genentech agreed to pay Gasherbrum a one-time, non‑refundable $100 million within 30 days of executing the agreement and low single‑digit royalties on net sales of GNE Products until patent expiration or a specified date. The license does not affect Structure’s ongoing programs, including aleniglipron and other GLP‑1 and related programs.

Key Details

• Date signed: December 30, 2025.
• Upfront payment: $100 million, one-time, non‑refundable (due within 30 days).
• Royalties: low single‑digit percentage on net sales, paid on a country‑by‑country basis until last valid Licensed Patent claim expires or a specified date.
• Scope: non‑exclusive, sublicensable license for CT‑996 products; GNE has no patent prosecution/enforcement rights; Gasherbrum may terminate if GNE challenges Licensed Patents (with customary exceptions).

Why It Matters

• This deal provides an immediate $100M cash infusion and potential ongoing royalty revenue, improving near‑term liquidity and creating a new revenue stream tied to CT‑996 sales.
• Because the license is non‑exclusive and excludes prosecution/enforcement rights, Structure retains freedom to continue advancing its own clinical programs (including aleniglipron and other GLP‑1, amylin/calcitonin, GIPR/GCGR programs) without being encumbered by the agreement.
• Termination and patent‑challenge protections help preserve Structure’s patent position and provide downside safeguards should GNE contest the patents.